Biodesix Inc
NASDAQ:BDSX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (4.5), the stock would be worth $40.34 (298% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.1 | $10.13 |
0%
|
| 3-Year Average | 4.5 | $40.34 |
+298%
|
| 5-Year Average | 6.3 | $56.97 |
+463%
|
| Industry Average | 1.7 | $15.66 |
+55%
|
| Country Average | 2.4 | $21.86 |
+116%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
$151.4m
|
/ |
Jan 2026
$88.5m
|
= |
|
|
$151.4m
|
/ |
Dec 2026
$110.9m
|
= |
|
|
$151.4m
|
/ |
Dec 2027
$132.1m
|
= |
|
|
$151.4m
|
/ |
Dec 2028
$155.1m
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Biodesix Inc
NASDAQ:BDSX
|
99.8m USD | 1.1 | -2.8 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
99.6B USD | 0.2 | 56.3 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
69.3B EUR | 0.3 | 13.6 | |
| US |
|
Cigna Corp
NYSE:CI
|
74.4B USD | 0.3 | 12.5 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
22.8B EUR | 1.2 | 23.3 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
22.7B EUR | 1 | 18.1 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
21.8B USD | 1.9 | 21.4 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21.7B USD | 1.6 | 24.7 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.8B EUR | 0.6 | 11.1 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
11.6B USD | 11.8 | -27.8 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.3B USD | 0.8 | 13.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.2 |
| Median | 2.4 |
| 70th Percentile | 4.1 |
| Max | 4 613 274.2 |
Other Multiples
Biodesix Inc
Glance View
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Boulder, Colorado and currently employs 218 full-time employees. The company went IPO on 2020-10-28. The firm uses its artificial intelligence (AI) platform, Diagnostic Cortex, to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus on lung disease. In addition to its diagnostic tests, it provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development and commercialization of companion diagnostics. The firm offers blood-based lung cancer tests across the lung cancer continuum of care, including Nodify XL2 and Nodify CDT tests, and GeneStrat and VeriStrat tests. The firm also offers three SARS-CoV-2 tests under the Biodesix WorkSafe testing program, such as Bio-Rad SARS-CoV-2 ddPCR test, Platelia SARS-CoV-2 Total Ab test and cPass SARS-CoV-2 Neutralization Antibody Test.
